Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098171 | 0.73 | NPBWR1 (0.32) | AKR1C3AKR1C2NPBWR1LMNATP53 | |
| SCHEMBL4105507 | 0.64 | GRIN1 (0.42) | AKR1C3AKR1C2NPBWR1MAPT | |
| SCHEMBL4090468 | 0.60 | MAPT (0.39) | NPBWR1LMNATP53MAPT | |
| SCHEMBL4091530 | 0.58 | MAP4K1 (0.38) | MAPT | |
| SCHEMBL29088121 | 0.53 | MRGPRX4 (0.59) | — | |
| SCHEMBL30080032 | 0.52 | DAO (0.46) | L3MBTL1MAPT | |
| SCHEMBL3985328 | 0.52 | IGF1R (0.39) | L3MBTL1LMNA | |
| SCHEMBL18164564 | 0.51 | MAOB (0.59) | L3MBTL1MAPT | |
| SCHEMBL25407647 | 0.51 | HSP90AA1 (0.55) | AKR1C3NPBWR1MAPT | |
| SCHEMBL8624597 | 0.51 | PTGER4 (0.51) | AKR1C3AKR1C2NPBWR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | AKR1C3 491/4885AKR1C2 655/4885NPBWR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.